EP0925280A1 - Nouveaux sels n proteges d'acide alpha-amino sulfinique, leur procede d'obtention, et les sulfonopeptides qui en derivent - Google Patents
Nouveaux sels n proteges d'acide alpha-amino sulfinique, leur procede d'obtention, et les sulfonopeptides qui en deriventInfo
- Publication number
- EP0925280A1 EP0925280A1 EP97931852A EP97931852A EP0925280A1 EP 0925280 A1 EP0925280 A1 EP 0925280A1 EP 97931852 A EP97931852 A EP 97931852A EP 97931852 A EP97931852 A EP 97931852A EP 0925280 A1 EP0925280 A1 EP 0925280A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- salt
- carbon
- chosen
- intermediate compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000002253 acid Substances 0.000 title abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 125000002252 acyl group Chemical group 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 12
- 150000001768 cations Chemical class 0.000 claims abstract description 7
- -1 hydroxyacid salt Chemical class 0.000 claims abstract description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 150000001721 carbon Chemical group 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 150000002148 esters Chemical group 0.000 claims description 7
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 7
- 150000002576 ketones Chemical class 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
- 125000000565 sulfonamide group Chemical group 0.000 claims description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 4
- 150000001261 hydroxy acids Chemical class 0.000 claims description 4
- 125000000962 organic group Chemical group 0.000 claims description 4
- 150000007854 aminals Chemical class 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 150000007530 organic bases Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 125000005616 oxoacid group Chemical group 0.000 claims 1
- 238000005576 amination reaction Methods 0.000 abstract description 6
- 150000002431 hydrogen Chemical group 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical group [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004715 keto acids Chemical class 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- BYUKRKALWSMYBW-UHFFFAOYSA-N O.[F] Chemical compound O.[F] BYUKRKALWSMYBW-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000003295 alanine group Chemical class N[C@@H](C)C(=O)* 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- JXUFISIHEZOBPI-UHFFFAOYSA-N amidosulfurous acid Chemical compound NS(O)=O JXUFISIHEZOBPI-UHFFFAOYSA-N 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- 150000008332 aminosulfonamides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 150000002541 isothioureas Chemical class 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- QLOAVXSYZAJECW-UHFFFAOYSA-N methane;molecular fluorine Chemical group C.FF QLOAVXSYZAJECW-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- OTYNBGDFCPCPOU-UHFFFAOYSA-N phosphane sulfane Chemical compound S.P[H] OTYNBGDFCPCPOU-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/32—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/04—Sulfinic acids; Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
Definitions
- the analogues of the transition state of the hydrolysis of the peptide bond (falling into the class of pseudopeptides) can act as false non-degradable substrates or as protease inhibitors, and therefore have great therapeutic interest, in particular for obtaining antibiotics, antihypertensives, analgesics, HIV protease inhibitors ...
- the rare derivatives of ⁇ -sulfinic amino acids described are not protected on nitrogen by an acyl protecting group, are not substituted at ⁇ , and are unstable.
- the invention therefore aims to overcome these drawbacks by proposing protected N acid salts ⁇ , amino sulfinic synthesized, stable, isolated or capable of being isolated, and the process for obtaining them.
- stable we mean that we can keep them at least 8 hours - notably several days - without alteration.
- the invention aims to propose a process making it possible to obtain said salts, the nitrogen substituent of which can be freely chosen, in particular from traditional acyl protective groups (Cbz, Boc, acetyl, etc.), and by particular distinct from the tosyle (PCH3C5H4SO2) and mesyl (CH3SO2) groups, so that the said salts can serve as precursors of ⁇ sulfonopeptides.
- the invention aims more particularly to provide salts as mentioned above in which the ⁇ carbon is substituted, in particular by a halogenated carbon group, and their process for obtaining.
- the invention thus aims to propose these salts which are precursors of sulfonopeptides, or even of sulfinopeptides, but which can also be isolated and used as such, in particular as N acylated analogs of natural ⁇ -amino carboxylic acids.
- the invention further aims to provide stable sulfonopeptics, namely, the stable synthesized ⁇ -sulfonopeptides, isolated or capable of being isolated, derived from these salts according to the invention.
- - sulfonopeptide any chain of amino acids comprising at least one ⁇ -amino sulfonamide residue
- - acyl any group or function of acyl type derived from an oxoacid in general, that is to say not only a carboxylic or thiocarboxylic acyl stricto sensu, but also groups or functions of acyl type derived from mineral acids such that sulfonic, phosphoric, thiophosphoric, phosphonic, or phosphinic acids, - ester: esters derived from acyls as mentioned above,
- - amide the aids originating from acyls as mentioned above, - CBz or Z: Benzyloxycarbonyl,
- - halogenated carbon group any group comprising at least one carbon atom and at least one halogen atom.
- the invention therefore relates to a process for obtaining protected N salts of ⁇ -amino sulfinic acid of formula:
- Y is an acyl - in particular a protective group adapted to be able to be substituted by a peptide group, and / or a peptide or pseudopeptide peptide group (for example sulfonopeptide) itself protected N
- R and R ′ may be chosen from hydrogen, a halogenated carbon group directly linked by a carbon atom to the ⁇ carbon of the salt, an alkyl or an aryl,
- M + is a cation, characterized in that:. an intermediate compound corresponding to the linear formula is chosen or prepared:
- R1 is an electron-withdrawing group, or to cyclic analogs of this formula, such as:
- R1 is chosen from:
- an -0-acyl ester function originating from an acyl as defined above, in particular a carboxylic ester function such as: O // -O- C or -O-SO3-, especially when R is -CF3,
- R is a fluorinated or chlorinated carbon group, in particular -CF3.
- R ' is hydrogen.
- said intermediate compound is added dropwise to an aqueous solution of HO - CH - SO2 Na rongalite.
- R2 is an organic group chosen from an alkyl; aryl; or a halogenated carbon group, in particular a fluorinated or chlorinated carbon group, more particularly a halogenated carbon group linked by a carbon to the carbon of the sulfinic hydroxyacid salt, advantageously -CF3.
- said intermediate compound is reacted in an anhydrous organic medium with a salt of sulfinic hydroxy acid of formula: HO - CH - S0 2 ⁇ , B +
- B is an organic base such as an amine.
- B is an aliphatic amine, such as NH (CgH- * -
- the aldehyde or the ketone is first reacted: 0 // R - C with the amide Y - NH2.
- R ' is preferably hydrogen, the aldehyde being generally more reactive than the ketone.
- the carbinolamine is activated by reacting it on a sulfonic acyl so as to obtain said intermediate compound where R1 is a sulfonic ester, in particular - O - SO3H or the corresponding anion - O - SO3-.
- the SO3 - Py complex is used where Py represents Pyridine.
- the protected salt N is separated from ⁇ -amino sulfinic acid by adding a water-soluble salt of dicyclohexylamrnoniurn (in particular a citrate), selective extraction in an organic solvent and evaporation.
- the dicyclohexylamrnoniurn salt formed with the aminosulfinate is selectively extracted in an organic extraction solvent (such as chloroform), while the other salts remain in the aqueous phase.
- This first situation and the corresponding variants of the process according to the invention are particularly applicable when Y is a protective group, distinct from tosyl and mesyl groups, and chosen to be able to be eliminated at least in part subsequently (and substituted by a peptide group) without destroying the sulfonamide function which can be formed from the salt, in particular under milder conditions than the tosyl and mesyl groups, and in particular when Y is chosen from benzyloxycarbonyl or tert-butyloxycarbonyl.
- Y is an acyl group, distinct from R ' 1 S0 2 , R''being methyl or PCH3C6H4,
- R is a halogenated carbon group directly linked by a carbon atom to the carbon ⁇ of the salt, or an alkyl or an aryl,
- R ' is chosen from hydrogen, a halogenated carbon group directly linked by a carbon atom to the carbon ⁇ of the salt, an alkyl or an aryl, M + is a cation. It should be noted that R is distinct from hydrogen.
- R is a fluorinated or chlorinated carbon group, in particular -CF3.
- R ' is hydrogen.
- Y is a protective group distinct from the tosyl and mesyl groups.
- Y is chosen so that it can be eliminated at least in part (and subsequently substituted by a peptide group) without destruction of the sulfonamide function which can be formed from the salt, in particular under milder conditions than the tosyl and mesyl groups.
- Y is in particular a group chosen from benzyloxycarbonyl or tert-butyloxycarbonyl.
- Y is an acyl group which can itself incorporate an ⁇ -amino acid residue N protected, in particular by an acyl function, or even a protected peptide or pseudo-peptide chain (for example sulfonopeptide) N, in particular by an acyl function. In this case, only the protective part of Y is eliminated.
- the salts according to the invention are then already themselves of sulfonopeptide nature.
- the new salts according to the invention are stable and can be isolated. They constitute analogs N acyls of the natural ⁇ -amino carboxylic acids and have in themselves the properties, in particular therapeutic, corresponding to this structure.
- the new salts according to the invention also make it possible to obtain particularly stable synthesized sulfonopeptides.
- the stable salts according to the invention are subjected to an electrophilic amination of the type: Y-NH-CR'R-S0 2 ⁇ , M + + H 2 N-0-S0 2 -0H -> Y-NH -CR'R-S0 2 -NH2 + HS0 - ⁇ , M « protest +
- Y-NH-CR'R-S02-NH2 is then used in conventional peptide synthesis reactions.
- the invention thus makes it possible to obtain the synthesized stable sulfonopeptides incorporating at least one residue of ⁇ -amino sulfonamide:
- R is a halogenated carbon group linked directly by a carbon atom to the carbon ⁇ of the residue; and R 'is chosen among hydrogen, a halogenated carbon group directly linked by a carbon atom to the carbon ⁇ of the residue, an alkyl or an aryl.
- R is a fluorinated or chlorinated carbon group, in particular -CF3.
- R ′ is in particular hydrogen, so that the sulfonopeptide is a natural peptide analog.
- the sulfonopeptides according to the invention are easy to isolate. The invention therefore also extends to these isolated sulfonopeptides.
- a fluorinated carbon group R such as -CF3 provides numerous advantages: it does not disturb the steric hindrance of the salt or of the sulfonopeptide; it can be easily followed by nuclear magnetic resonance and therefore constitutes a tracer element; it gives the molecule an ability to cross cell membranes and improves its therapeutic effectiveness ...
- the invention also relates to a process for obtaining the new salts and the sulfonopeptides comprising in combination all or part of the characteristics mentioned above or below.
- Y is Z
- R is CF3
- R ' is H
- M + is H 2 N + (C 6 H-
- Y is Tos; R is CF3; R 'is H; M + is H 2 N + (C 6 H- ⁇ - * ) 2 * A 0.41 g (1.19 mmol, 1.5 eq.) Of the sulfinic hydroxyacid HOCHCF 3 S ⁇ 2 ⁇ H2N + (C6H-- - *) 2 (R2 is - -CF3 and M 'is identical to M; Tetrahedron 1993, 2469) and 0.29 g (0.75 mmol) of the diacylaminal (TosNH) 2 CHCF3 (Chem. Ber.
- the product can be recrystallized, without heating, from a MeCN-CHCl3 mixture.
- MeCN-H 0 mixture the product is hydrolyzed in less than an hour and after addition of dicyclohexylamine, it is isolated with an almost quantitative yield, TosNHCH2S03 _ H2N (C5H-
- the product is stable in MeCN-H2 ⁇ solution and is recognized quantitatively after 24 h by adding an excess of water.
- the protective group Z is easy to remove, for example by catalytic hydrogenation, to obtain the new sulfonopeptide according to the invention in salt form: N + H 3 - CH CF 3 - SO2 - NH 2 - A ⁇
- This alanine analog is of major therapeutic interest, in particular as an antibiotic.
- the new monosulfonopeptides of the invention are stable, in particular when one chooses -CF3 for the group R.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609845A FR2751973B1 (fr) | 1996-07-31 | 1996-07-31 | Nouveaux sels n proteges d'acide alfa-amino sulfinique, leur procede d'obtention, et les sulfonopeptides qui en derivent |
FR9609845 | 1996-07-31 | ||
PCT/FR1997/001185 WO1998004522A1 (fr) | 1996-07-31 | 1997-07-03 | NOUVEAUX SELS N PROTEGES D'ACIDE α-AMINO SULFINIQUE, LEUR PROCEDE D'OBTENTION, ET LES SULFONOPEPTIDES QUI EN DERIVENT |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0925280A1 true EP0925280A1 (fr) | 1999-06-30 |
Family
ID=9494811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97931852A Withdrawn EP0925280A1 (fr) | 1996-07-31 | 1997-07-03 | Nouveaux sels n proteges d'acide alpha-amino sulfinique, leur procede d'obtention, et les sulfonopeptides qui en derivent |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0925280A1 (fr) |
FR (1) | FR2751973B1 (fr) |
WO (1) | WO1998004522A1 (fr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387671A (en) * | 1990-12-27 | 1995-02-07 | Abbott Laboratories | Hexa- and heptapeptide anaphylatoxin-receptor ligands |
-
1996
- 1996-07-31 FR FR9609845A patent/FR2751973B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-03 WO PCT/FR1997/001185 patent/WO1998004522A1/fr not_active Application Discontinuation
- 1997-07-03 EP EP97931852A patent/EP0925280A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9804522A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998004522A1 (fr) | 1998-02-05 |
FR2751973A1 (fr) | 1998-02-06 |
FR2751973B1 (fr) | 1998-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2486020B1 (fr) | Procede de synthese de l'ergothioneine et analogues | |
EP0133127B1 (fr) | Nouvelles phosphines chirales sulfonées, leur préparation et leur emploi en catalyse asymétrique | |
FR2763331A1 (fr) | Procede de synthese de sulfonimides et de leurs sels | |
EP1144346B1 (fr) | Procede de preparation de radicaux nitroxyde beta-phosphores | |
BE1012819A6 (fr) | Procede de preparation du maleate de fluvoxamine. | |
EP0925280A1 (fr) | Nouveaux sels n proteges d'acide alpha-amino sulfinique, leur procede d'obtention, et les sulfonopeptides qui en derivent | |
EP2084125B1 (fr) | Derives d'aminobenzocycloheptene, leurs procedes de preparation et leur utilisation en therapeutique | |
RU2548153C2 (ru) | Способ синтеза 2-тиогистидина и его аналогов | |
EP1620390B1 (fr) | Procede de synthese de la 4-hydroxyisoleucine et de ses derives | |
EP0562659B1 (fr) | Procédé de synthèse peptidique et nouveaux intermédiaires de synthèse | |
JP2555244B2 (ja) | 新規な光学活性tert−ロイシン・1−(4−メチルフェニル)エタンスルホン酸塩およびその製造法 | |
JP2002515004A (ja) | アミノ酸誘導ジアミノプロパノール | |
EP0117861B1 (fr) | Procédé d'obtention de la vincristine | |
EP0659175B1 (fr) | Derives d'(amino-3 phenyl)-1 ethanesulfonate d'alkylammonium optiquement actifs, leur preparation et leur utilisation | |
JPH078855B2 (ja) | スルホニウム化合物 | |
FR2571055A1 (fr) | Procede de preparation de la 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine | |
EP0539451B1 (fr) | Vinylsulfonyl pristinamycine et sa preparation | |
CA3119871A1 (fr) | Nouvelle voie de synthese de diazirines, enrichies ou non en azote-15 | |
FR2504525A1 (fr) | Procede de preparation d'oligopeptides lysine-tryptophane, de leurs derives et de leurs sels physiologiquement utilisables | |
EP0853612B1 (fr) | Derives d'alfa-hydrazinoacides et procede pour les fabriquer | |
FR2667065A1 (fr) | Procede pour preparer la 1-[(2s)-3-mercapto-2-methyl-1-oxopropyl]-l-proline. | |
EP0374014A2 (fr) | Nouveaux composés organo-manganeux, leur préparation et applications | |
WO1990010009A1 (fr) | Sels de phosphonium comme reactifs de couplage peptidique | |
JPH0859595A (ja) | N−モノ−t−ブチルオキシカルボニルアルキレンジアミンの精製法 | |
WO2006082228A1 (fr) | Procede de synthese de derives de la cysteine, notamment du thiocarbaester, utiles en tant que produits intermediaires dans la synthese de medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19981218 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IE IT LI NL |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
17Q | First examination report despatched |
Effective date: 20000816 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010103 |